Your browser doesn't support javascript.
loading
Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
Gaiteiro, Cristiana; Soares, Janine; Relvas-Santos, Marta; Peixoto, Andreia; Ferreira, Dylan; Paulo, Paula; Brandão, Andreia; Fernandes, Elisabete; Azevedo, Rita; Palmeira, Carlos; Freitas, Rui; Miranda, Andreia; Osório, Hugo; Prieto, Jesús; Lima, Luís; Silva, André M N; Santos, Lúcio Lara; Ferreira, José Alexandre.
  • Gaiteiro C; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal.
  • Soares J; RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
  • Relvas-Santos M; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal.
  • Peixoto A; Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • Ferreira D; Center for Applied Medical Research (Centro de Investigación Médica Aplicada, CIMA), University of Navarra, 31008 Pamplona, Navarra, Spain.
  • Paulo P; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal.
  • Brandão A; RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
  • Fernandes E; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal.
  • Azevedo R; Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • Palmeira C; REQUIMTE-LAQV, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.
  • Freitas R; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal.
  • Miranda A; RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
  • Osório H; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal.
  • Prieto J; Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • Lima L; Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal.
  • Silva AMN; Institute for Biomedical Engineering (INEB), University of Porto, 4200-135 Porto, Portugal.
  • Santos LL; REQUIMTE-LAQV, Department of Chemistry and Biochemistry, Faculty of Sciences of the University of Porto, 4169-007 Porto, Portugal.
  • Ferreira JA; Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal.
Theranostics ; 12(7): 3150-3177, 2022.
Article en En | MEDLINE | ID: mdl-35547758
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2022 Tipo del documento: Article